| WB | 咨询技术 | Human,Mouse,Rat,Fruitfly,Nematode |
| IF | 咨询技术 | Human,Mouse,Rat,Fruitfly,Nematode |
| IHC | 咨询技术 | Human,Mouse,Rat,Fruitfly,Nematode |
| ICC | 1/50-1/200 | Human,Mouse,Rat,Fruitfly,Nematode |
| FCM | 咨询技术 | Human,Mouse,Rat,Fruitfly,Nematode |
| Elisa | 咨询技术 | Human,Mouse,Rat,Fruitfly,Nematode |
| Aliases | fast skeletal muscle; MYH3; HEMHC; Myosin-1; Myosin heavy chain 2x; MyHC-2x; Myosin heavy chain IIx/d; MyHC-IIx/d; Myosin heavy chain; skeletal muscle; adult 1 |
| Entrez GeneID | 4619 |
| clone | 8D12 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat,Fruitfly,Nematode |
| Immunogen | Synthetic Peptide of Myosin Heavy Chain |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于MYH1抗体的3篇参考文献示例(内容为虚构，仅供格式参考)：
---
1. **文献名称**：*Autoantibodies to MYH1 in Idiopathic Inflammatory Myopathies: A Novel Biomarker*
**作者**：Smith A, et al.
**摘要**：本研究首次报道MYH1抗体在特发性炎症性肌病(IIM)患者血清中的特异性表达，提示其可能作为区分坏死性肌炎与其他亚型的潜在生物标志物，并与疾病活动度相关。
---
2. **文献名称**：*MYH1 Antibodies in Paraneoplastic Neurological Syndromes*
**作者**：Chen L, et al.
**摘要**：通过回顾性分析，发现MYH1抗体在合并胸腺瘤的副肿瘤神经综合征患者中高表达，提示其可能参与肿瘤相关的自身免疫反应机制。
---
3. **文献名称**：*Proteomic Identification of MYH1 as an Autoantigen in Myasthenia Gravis*
**作者**：Wang X, et al.
**摘要**：利用蛋白质组学技术筛选重症肌无力(MG)患者血清，发现MYH1抗体与乙酰胆碱受体抗体共存，可能扩展MG的自身抗体谱系并指导个体化治疗。
---
注：以上文献为模拟示例，实际研究中需通过PubMed等数据库检索真实文献。
MYH1 (myosin heavy chain 1) is a sarcomeric protein encoded by the *MYH1* gene, primarily expressed in fast-twitch skeletal muscle fibers. As part of the myosin II family, it plays a critical role in muscle contraction by interacting with actin filaments to generate mechanical force. MYH1 antibodies are autoantibodies that target this protein and are clinically associated with autoimmune myopathies, particularly in the context of paraneoplastic syndromes or idiopathic inflammatory myopathies.
The detection of MYH1 antibodies is significant in diagnosing rare neuromuscular disorders, such as immune-mediated necrotizing myopathy (IMNM), where they may serve as a biomarker for disease stratification. Their presence often correlates with severe muscle weakness, elevated creatine kinase levels, and histological evidence of muscle necrosis. Notably, MYH1 autoimmunity has been reported in patients with underlying malignancies, suggesting a potential paraneoplastic origin in some cases.
In research, MYH1 antibodies are utilized to study skeletal muscle differentiation, regeneration, and pathophysiology. Commercial assays, including immunohistochemistry and immunoblotting, are employed to detect these antibodies in patient sera. Understanding MYH1 antibody dynamics aids in elucidating autoimmune mechanisms and refining therapeutic strategies, such as immunosuppressive therapies targeting B-cell or plasma cell activity. Ongoing studies aim to clarify their pathogenic role and diagnostic utility in overlapping myositis syndromes.
×
